My research interest centres on the molecular evolution of human cancers, with particular reference to the role of DNA methylation and transcriptional alterations in driving functional changes.

In my clinical work, I was the Medical Director and Department Chair of Oncology, New Hope Cancer Centre, Beijing United Hospital, China from 2018 until 2023, where we enjoyed a close working relationship with Peking University Cancer Hospital, and were GCP-accredited for recruiting patient to clinical trials. 

Before returning in 2009 to Sydney, where I helped to set up The Kinghorn Cancer Centre, I had helped to set up major new Cancer Centres in Singapore and The University of Hong Kong.

In 1996 I patented the invention of phosphorylation-state-specific antibodies, which invention has since earned approximately US$20m royalties for Harvard University and Dana-Farber Cancer Institute, and led to development of a number of successful diagnostic reagent companies.

With the advent of powerful (non-generative) AI, we are now working on a mathematical proof for our discovery of programmed genetic instability (PGI), which we feel nicely complements Sydney Brenner's discovery in the late 1980s of programmed cell death (PCD).